



March 22, 2022

To whom it may concern,

Company: Japan Lifeline Co., Ltd.  
Representative: Keisuke Suzuki, President and CEO  
(Code: 7575 TSE 1st Section)  
Contact person: Kenji Yamada, Senior Vice President,  
Corporate Administration Headquarters  
(TEL. +81-3-6711-5200)

### **Japan Lifeline Announces the Launch of Wallaby Medical’s Avenir Intravascular Embolic Coil System**


Japan Lifeline Co., Ltd. (“Japan Lifeline”) is pleased to announce that the company has entered into an exclusive distribution agreement on December 2021 with Wallaby Medical for the Avenir Coil System (“Avenir”), an intravascular embolic coil system, for the territory in Japan. The Avenir is scheduled to be launched in the neurovascular space from April 2022.

Avenir is an intravascular embolic coil system mainly used in the treatment of cerebral aneurysms. A cerebral aneurysm is a bulging aneurysm in the wall of a cerebral artery, and an embolic coil is inserted into the aneurysm to block the inflow of blood and prevent the aneurysm from rupturing (subarachnoid hemorrhage). In Japan, approximately 30,000 cerebral aneurysms are treated annually, and about half of these are treated percutaneously using embolic coils. The number of treatments using embolic coils has been increasing in recent years because they are less invasive than surgical procedures. The Avenir received U.S. FDA approval in 2018 and CE Mark the following year. It is currently marketed in more than 30 countries and regions, with tens of thousands units sold worldwide each year. In Japan, Avenir received regulatory approval in 2020 for the treatment of cerebral aneurysms and other cerebrovascular anomalies and embolization of arteries and veins in the peripheral vascular system.

Existing embolic coils currently used in treatment of cerebral aneurysms require a dedicated detachment - handle or box for implantation. On the other hand, the Avenir does not require a dedicated detachment device and can be instantly released with a simple manipulation of the device, thereby contributing to shortening the time required for the procedure. In addition, the Avenir is available in 110 different sizes and two shapes, and is designed with six different levels of coil softness. These features make it possible to effectively treat a wide range of patients with the most appropriate product.

In the cardiovascular field, Japan Lifeline deals in vascular grafts, open stent grafts and abdominal stent grafts. Since the Avenir is also used for embolization of peripheral abdominal vessels during abdominal stent graft treatment, the company has been selling the Avenir since December 2021, prior to sales in the neurovascular space, and has already received a certain level of recognition by cardiovascular physicians.

The neurovascular space is a totally new business area for Japan Lifeline. The company sees this area as a priority area of growth with high potential. Japan Lifeline will strive to tap into the market with the Avenir and provide medical professionals with a full range of excellent medical devices through introducing further new products in the same space.



Intravascular Embolic Coil System  
“Avenir Coil System”

#### About Wallaby Medical

Wallaby Medical focuses on developing and commercializing medical device products for treating stroke. Wallaby’s products include the Avenir Coil System which is a technically differentiated neuro embolic coil system for treating intracranial aneurysms and other neurovascular abnormalities, the Esperance Aspiration Catheter approved for ischemic stroke and hemorrhagic stroke treatment procedures in the US, and the Esperance Distal Access Catheter approved for delivery assistance in China. In addition, Wallaby has a full range of neurovascular products under development. Wallaby’s products are commercialized in over 30 countries and regions. For more information, visit [www.wallabymedical.com](http://www.wallabymedical.com).